- In February 2025, Biogen and Stoke Therapeutics have partnered to develop and commercialize zorevunersen, a potential first-in-class disease-modifying therapy for Dravet syndrome. This investigational antisense oligonucleotide targets the SCN1A gene to reduce seizures and improve cognition. A Phase 3 study begins in 2025, with regulatory filings expected in 2027. Stoke retains U.S. rights, while Biogen handles North America commercialization
- In March 2025, Biogen will establish its new North America headquarters at Kendall Common in Cambridge, Massachusetts, as part of a multi-year real estate consolidation. The state-of-the-art facility, set to open in 2028, will foster collaboration, innovation, and sustainability while housing Biogen’s research, development, and commercial teams alongside the Biogen CoLab for life sciences education
- In March 2025, Ionis Pharmaceuticals, Inc. announced that Wainzua (Eplontersen) has been approved by the European Medicines Agency (EMA) for the treatment of hereditary transthyretin amyloidosis (hATTR). This antisense therapy targets the underlying cause of the disease, offering a new therapeutic option for patients suffering from this rare, life-threatening condition
- In February 2024, Pfizer Inc. and UT Southwestern Medical Center have partnered to develop advanced RNA delivery technologies for genetic medicine. This collaboration integrates UTSW’s expertise in Lipid Nanoparticle (LNP) delivery systems with Pfizer’s RNA innovation to enhance RNA-based therapies. The research aims to expand gene editing applications, improve targeted delivery, and accelerate the development of next-generation genetic medicines
- In January 2022, Pfizer Inc. has partnered with Acuitas Therapeutics to expand Lipid Nanoparticle (LNP) delivery technology for mRNA-based vaccines and therapeutics. This agreement allows Pfizer to license Acuitas’ LNP technology for up to 10 targets, strengthening its mRNA strategy. The collaboration enhances vaccine development and enables next-generation genetic medicines, building on the success of COMIRNATY, the Pfizer-BioNTech COVID-19 vaccine
Frequently Asked Questions
Key trends in the North America nucleic acid therapeutics, sport food additives, and skin care market include the rise of personalized and gene-based therapies, growing demand for clean-label and functional wellness products.
Challenges in the North America nucleic acid therapeutics, sport food additives and skin care market include Low public awareness and slow adoption rates and Intellectual property complexities and patent-related hurdles.
The nucleic acid therapeutics segment is expected to dominate the market due to rapid advancements in gene editing, personalized medicine, and RNA therapies, offering targeted treatments for various diseases with high efficacy and minimal side effects.
